| NASDAQ (usa) |
 |
6715.56 | -12.11 | -0.18% |
| FTSE 100 (london) |
|
7487.96 | -5.12 | -0.07% |
| DAX (german) |
 |
13465.51 | 235.94 | 1.78% |
| NIKKEI 225 (japan) |
|
22420.08 | 408.47 | 1.86% |
| Hang - Seng (hong kong) |
|
28594.06 | 348.52 | 1.23% |
| NIFTY - 50 (india) | ||||
| Straits Times (singapore) |
|
3391.61 | 17.53 | 0.52% |
| KOSPI (korea) |
|
2556.47 | 33.04 | 1.31% |
| All Ordinaries (australia) |
|
6005.30 | 28.90 | 0.48% |
| BOVESPA (brazil) |
|
74092.76 | -215.73 | -0.29% |
Bolt Biotherapeutics Inc (NASDAQ: BOLT)
BOLT Technical Analysis
5
| As on 9th Jun 2023 BOLT SHARE Price closed @ 1.64 and we RECOMMEND Strong Sell for LONG-TERM with Stoploss of 2.41 & Strong Sell for SHORT-TERM with Stoploss of 3.78 we also expect STOCK to react on Following IMPORTANT LEVELS. |
BOLTSHARE Price
| Open | 1.65 | Change | Price | % |
| High | 1.68 | 1 Day | -0.02 | -1.20 |
| Low | 1.63 | 1 Week | -0.07 | -4.09 |
| Close | 1.64 | 1 Month | 0.02 | 1.23 |
| Volume | 28293 | 1 Year | -2.68 | -62.04 |
| 52 Week High 4.94 | 52 Week Low 1.26 | ||||
NASDAQ USA Most Active Stocks
| TSLA | 244.40 | 4.06% |
| TTOO | 0.07 | -12.50% |
| SOFI | 8.18 | 0.74% |
| FFIE | 0.33 | 6.45% |
| PONO | 1.72 | 2.38% |
| AMD | 124.92 | 3.20% |
| IDEX | 0.06 | 0.00% |
| NKLA | 0.70 | 14.75% |
| AMZN | 123.43 | -0.66% |
| AAPL | 180.96 | 0.22% |
NASDAQ USA Top Gainers Stocks
NASDAQ USA Top Losers Stocks
| BOLT Daily Charts |
BOLT Intraday Charts |
Whats New @ Bazaartrend |
BOLT Free Analysis |
|
|
BOLT Important Levels Intraday
| RESISTANCE | 1.74 |
| RESISTANCE | 1.71 |
| RESISTANCE | 1.69 |
| RESISTANCE | 1.67 |
| SUPPORT | 1.61 |
| SUPPORT | 1.59 |
| SUPPORT | 1.57 |
| SUPPORT | 1.54 |
BOLT Forecast April 2024
| 4th UP Forecast | 5.42 |
| 3rd UP Forecast | 4.21 |
| 2nd UP Forecast | 3.46 |
| 1st UP Forecast | 2.71 |
| 1st DOWN Forecast | 0.57 |
| 2nd DOWN Forecast | -0.18 |
| 3rd DOWN Forecast | -0.93 |
| 4th DOWN Forecast | -2.14 |
BOLT Weekly Forecast
| 4th UP Forecast | 3.26 |
| 3rd UP Forecast | 2.74 |
| 2nd UP Forecast | 2.42 |
| 1st UP Forecast | 2.10 |
| 1st DOWN Forecast | 1.18 |
| 2nd DOWN Forecast | 0.86 |
| 3rd DOWN Forecast | 0.54 |
| 4th DOWN Forecast | 0.02 |
BOLT Forecast2024
| 4th UP Forecast | 9.31 |
| 3rd UP Forecast | 6.85 |
| 2nd UP Forecast | 5.33 |
| 1st UP Forecast | 3.81 |
| 1st DOWN Forecast | -0.53 |
| 2nd DOWN Forecast | -2.05 |
| 3rd DOWN Forecast | -3.57 |
| 4th DOWN Forecast | -6.03 |
Bolt Biotherapeutics Inc ( NASDAQ USA Symbol : BOLT )
Sector : Healthcare And Other Stocks in Same Sector
Sector : Healthcare And Other Stocks in Same Sector
BOLT Business Profile
Bolt Biotherapeutics, Inc., a clinical-stage immuno-oncology company, engages in the discovery, development, and commercialization of pharmaceutical products. The company develops BDC-1001, a human epidermal growth factor receptor 2 (HER2) for the treatment of patients with HER2-expressing solid tumors, including HER2-low tumors; and BDC-2034, a carcinoembryonic antigen program for colorectal, non-small cell lung, pancreatic, and breast cancers. It is also developing programmed cell death-ligand 1 program for tumors that are nonresponsive to immune checkpoint blockade; and myeloid modulators. The company was formerly known as Bolt Therapeutics, Inc. and changed its name to Bolt Biotherapeutics, Inc. in July 2015. Bolt Biotherapeutics, Inc. was incorporated in 2015 and is headquartered in Redwood city, California. Address: 900 Chesapeake Drive, Redwood City, CA, United States, 94063
© 2005-2023 BazaarTrend.com All rights reserved.
Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service
Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service